Guy Chamberland, M.Sc., Ph.D., CEO and Chief Regulatory Officer of Tetra Bio-Pharma

Portrait

Dr. Guy Chamberland, M.Sc., Ph.D., Master Herbalist, is a drug development specialist with 25 years experience in the pharmaceutical industry. Having obtained a Master’s of Science and Doctorate (PhD) degree in biomedical sciences, he has developed an expertise in drug safety and regulatory affairs while working in the pharmaceutical and biotechnology industries. He has specific expertise in the development of drug-device combination products, biologics, and botanical medicines.

Dr. Chamberland has served as Tetra Bio-Pharma’s Chief Executive Officer and Chief Regulatory Officer since October 15, 2018. He is responsible for the transformation of the biotechnology company into a pharmaceutical firm that discovers, develops and commercializes cannabinoid-based pharmaceuticals. The mandate began with a company of less than 10 employees and today has over 50 employees specialized in regulatory affairs, clinical research, manufacturing compliance, clinical trial product manufacturing, clinical operations and research and development. Dr. Chamberland oversees the scientific and regulatory requirements for drug and medical device approval (i.e., vaporizers) and strategic planning for corporate development.

Dr. Chamberland has become a thought leader in botanical medicine, publishing, lecturing and delivering continuing education workshops to health professionals on the use of plants for the treatment of pain, anxiety, insomnia, and wound healing. He is a Professor of Botanical Medicine and Principles of Clinical Research at the École d’Enseignement Supérieur de Naturopathie du Québec (EESNQ) and the French language equivalent of the Canadian College of Naturopathic Medicine (CCNNM). He earned a diploma in Proficiency in Herbal Prescription from the Australian College of Phytotherapy, and Certified Herbalist and Master Herbalist diplomas from the Dominion College of Canada. Dr. Chamberland received a B.Sc. in Agriculture form McGill University, an M.Sc. in Veterinary Anatomy and Physiology and a Ph.D. in Biomedical Sciences (toxicology) from the University of Montreal.

Dr. Chamberland is a pioneer in drug-device combination products. He developed and executed the regulatory strategy for two novel products and obtained marketing approval. In 2002, he was invited by the FDA to present at the FDA Public Hearing to regulate combination products. He spent 7-years as a member of the Scientific Advisory Committee of a Venture Capital fund and 6-years on a Health Canada Expert Committee. He was also employed by the Victhom Laboratory; Angiogene Inc.; CATO Research Ltd; and MDS Pharma, respectively.

Jean-François Boily, CPA, Chief Financial Officer

Portrait

Before joining Tetra Bio-Pharma, Mr. Boily served as Vice-President and Financial Officer at Acasti Pharma Inc., a dual-listed (TSXV & Nasdaq) biopharmaceutical innovator focused on the research and development of prescription drugs using Omega-3 fatty acids derived from krill oil for treatment of hypertriglyceridemia. He raised C$50M to fund the Trilogy Phase 3 program and later set-up an “at-the-market” (or ATM) program for aggregate proceeds of up to US$ 30M with sales on Nasdaq. He also migrated financial reporting to US-Gaaps to become a fully compliant SEC registrant and filed a registration statement on Form S-3 with the SEC to register up to US$200 million of common shares, warrants and units.

Prior to Acasti, Mr. Boily served as a Director of Finance & Information Technology at Innovaderm Research Inc., a North American contract research organization (CRO) specialized in dermatology. Working closely with the President and founder, Mr. Boily undertook a vast financial, IT and growth mandate and increased revenues and profits over 25%.

Formerly, Mr. Boily was a Director of Finance at Teva Canada Innovation where he oversaw and reported on the financial conduct of all clinical R&D activities and managing branded product launches in the therapeutic areas of central nervous system (CNS), respiratory, oncology and pain care.

Mr. Boily holds a Bachelor’s of Science in Accounting from HEC Montreal and is a Quebec-Chartered Public Accountant (CPA).

Steeve Néron, Chief Commercial Officer

Portrait

Mr. Néron has more than three decades of experience in the pharmaceutical industry where challenging the reimbursement landscape factored prominently in his role, with demonstrated success in numerous therapeutic sectors including cardiology, rheumatology, endocrinology, women’s health, asthma/COPD, OTC and dermatology. Prior to joining Tetra Bio-Pharma he occupied a senior marketing position at Bausch Health Canada. Steeve has held various marketing, sales, finance, material management and business development positions and has worked to launch or rejuvenate numerous market-leading pharmaceutical brands including Aerius™ (antihistamine), Altace™ (hypertension), Ezetrol™ (cholesterol), Eliquis™ (anti-coagulant), Lodalis™ (cholesterol) and Contrave™ (Obesity).

Mr. Neron holds a Bachelor’s degree in Business Administration (BBA) in Marketing from Université du Québec in Chicoutimi (QC).

Melanie Kelly, Ph.D., Chief Scientific Officer

Portrait

Melanie Kelly is a Professor In Pharmacology and Ophthalmology at Dalhousie University in Halifax with expertise in preclinical and clinical research design, novel drug development, medical cannabis and cannabinoid based drugs.

A respected research professional with a Doctor of Philosophy (PhD) focused on drug discovery and molecular pharmacology, Dr. Kelly has significant research experience in the field of G protein coupled receptors and endocannabinoid/cannabinoid signaling. She is considered to be an expert in the cannabinoid drug development space.

Her primary research expertise is pharmacology, specifically receptors and cell signaling pathways. Her work has examined pathways important to the survival of retinal ganglion cells in experimental models of glaucoma and has made use of gene mutations, to explore signaling pathways involved in retinal progenitor cell growth and development. Dr. Kelly’s current research addresses the pharmacology of the endocannabinoids and lipid signaling in the mammalian eye, with a specific focus on the regulation of intraocular pressure and interactions between glial cells and microvasculature in the regulation of retinal blood flow.

She is a member of the International Cannabis Research Society.

Graham Wood, Ph.D., Chief Operating Officer

Portrait

Dr. Graham Wood joined Tetra Bio-Pharma in September 2020 as Chief Operating Officer, to lead the regulated drug development activities. Dr. Wood has over twenty years of drug development experience. Most recently he was Chief Scientific Officer at Neptune Wellness, where he leads product development and clinical research activities. Prior to that, he was Chief R&D Officer at Altasciences where he was responsible for developing innovative nonclinical and clinical techniques and overseeing the clinical pharmacology study designs. He was also Chief Executive Officer at Manna Research, which he grew from a single clinical research site to the largest family practice site network in Canada. As President at Cetero Research, he was responsible for the early and late stage clinical development conducted at the Cetero facilities in Toronto and Miami. He holds a PhD in Neurology and Neurosurgery from McGill University and worked as Fellow at the National Institute of Health.